Reuters logo
BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​
2017年8月10日 / 凌晨5点23分 / 2 个月前

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​

Aug 10 (Reuters) - BASILEA PHARMACEUTICA AG:

* ‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​

* ‍COMPLETED LICENSE AGREEMENT WITH PFIZER FOR CRESEMBA IN EUROPE​

* CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017 AND A SIGNIFICANTLY REDUCED OPERATING LOSS OF CHF 17.7 MILLION IN FIRST HALF-YEAR (H1 2016: CHF 24.8 MILLION; -29%)

* ‍REPORTED CHF 253.1 MILLION IN CASH AND INVESTMENTS AS OF JUNE 30, 2017​

* UPDATES ITS FINANCIAL GUIDANCE FOR 2017

* ‍H1 NET LOSS NARROWS TO 20.6 CHF MILLION​

* ‍NOW ANTICIPATES ITS 2017 PRODUCT SALES TO BE APPROXIMATELY CHF 13 MILLION, AND A PARTICIPATION IN PARTNER SALES THROUGH ROYALTIES OF APPROXIMATELY CHF 15 MILLION​

* TOTAL OPERATING EXPENSES FOR 2017, NET OF ANTICIPATED BARDA REIMBURSEMENTS, ARE ESTIMATED AT CHF 9-10 MILLION ON AVERAGE PER MONTH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below